Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.

Authors

Ray O Bahado-Singh, Beaumont Health
Sangeetha Vishweswaraiah, Beaumont Health
Buket Aydas
Ali Yilmaz, Beaumont Health
Raghu P Metpally
David J Carey
Richard C Crist
Wade H Berrettini
George D. Wilson, Beaumont Health
Khalid Imam, Beaumont Health
Michael Maddens, Beaumont Health
Halil Bisgin
Stewart F. Graham, Beaumont Health
Uppala Radhakrishna, Beaumont Health

Document Type

Article

Publication Date

3-31-2021

Publication Title

PLoS One

Abstract

We evaluated the utility of leucocyte epigenomic-biomarkers for Alzheimer's Disease (AD) detection and elucidates its molecular pathogeneses. Genome-wide DNA methylation analysis was performed using the Infinium MethylationEPIC BeadChip array in 24 late-onset AD (LOAD) and 24 cognitively healthy subjects. Data were analyzed using six Artificial Intelligence (AI) methodologies including Deep Learning (DL) followed by Ingenuity Pathway Analysis (IPA) was used for AD prediction. We identified 152 significantly (FDR p

Volume

16

Issue

3

First Page

e0248375

Recommended Citation

Bahado-Singh RO, Vishweswaraiah S, Aydas B, Yilmaz A, Metpally RP, Carey DJ, Crist RC, Berrettini WH, Wilson GD, Imam K, Maddens M, Bisgin H, Graham SF, Radhakrishna U. Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease. PLoS One. 2021 Mar 31;16(3):e0248375. doi: 10.1371/journal.pone.0248375. PMID: 33788842; PMCID: PMC8011726.

DOI

10.1371/journal.pone.0248375

ISSN

1932-6203

PubMed ID

33788842